^
    Back
    Association details:
    Biomarker:EGFR exon 20 insertion + EGFR G719X + EGFR L858R
    Cancer:Non Small Cell Lung Cancer
    Drug:Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2020
    Title:

    P84.22 - Outcomes of TKI Treatment in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Real-World Study in Argentina

    Published date:
    01/12/2021
    Excerpt:
    Advanced NSCLC patients harboring uncommon (other than L858R and exon 19 deletion) EGFR mutations at baseline tissue biopsy were selected...afatinib also led response in a triple EGFR mutations tumor (exon 20 insertion + G719X + L858R)…